Search results for Sibrotuzumab

Sibrotuzumab Biosimilar – Anti-FAP mAb – Research Grade, ProteoGenix, PX-TA1203

Description of Sibrotuzumab Biosimilar - Anti-FAP mAb - Research Grade Introduction Sibrotuzumab Biosimilar, also known as Anti-FAP mAb, is a monoclonal antibody that targets the fibroblast activation protein (FAP). FAP is a cell surface protein that is highly expressed in cancer-associated fibroblasts, making it an attractive therapeutic target for various types of cancer. In this article, we will discuss the structure, activity, and potential applications of Sibrotuzumab Biosimilar in cancer research. Structure of Sibrotuzumab Biosimilar Sibrotuzumab Biosimilar is a recombinant humanized monoclonal antibody that is produced using a combination of genetic engineering and cell culture techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to FAP, while the constant region determines the antibody’s effector functions. The antibody has a molecular weight of approximately 150 kDa and a half-life of 10-14 days in the human body. It is stable at physiological pH and temperature, making it suitable for therapeutic use. Activity of Sibrotuzumab Biosimilar Sibrotuzumab Biosimilar binds specifically to FAP, a protein that is overexpressed in the tumor stroma of various types of cancer, including breast, lung, and pancreatic cancer. FAP is involved in tumor growth, invasion, and metastasis, making it an attractive target for cancer therapy. Upon binding to FAP, Sibrotuzumab Biosimilar can inhibit FAP’s enzymatic activity, which is responsible for promoting tumor growth and metastasis. It can also trigger an immune response, leading to the destruction of FAP-expressing cells by the body’s immune system. Applications of Sibrotuzumab Biosimilar Sibrotuzumab Biosimilar has shown promising results in preclinical and clinical studies as a potential therapeutic agent for various types of cancer. Some of its potential applications include: Treatment of solid tumors Sibrotuzumab Biosimilar has been studied as a potential treatment for solid tumors, such as breast, lung, and pancreatic cancer. In a phase II clinical trial, it showed promising results in combination with chemotherapy in patients with advanced pancreatic cancer, leading to improved overall survival and progression-free survival. Targeted therapy Due to its specific binding to FAP, Sibrotuzumab Biosimilar has the potential to be used as a targeted therapy for cancer. This means that it can selectively target and destroy cancer cells while sparing healthy cells, reducing the risk of side effects. Imaging agent Sibrotuzumab Biosimilar can also be used as an imaging agent to detect FAP-expressing tumors. This can aid in the diagnosis and staging of cancer, as well as monitoring the response to therapy. Research tool In addition to its potential therapeutic applications, Sibrotuzumab Biosimilar can also be used as a research tool to study the role of FAP in cancer progression and to develop new treatments targeting FAP. Conclusion In summary, Sibrotuzumab Biosimilar is a promising monoclonal antibody that targets FAP, a protein that is overexpressed in various types of cancer. Its specific binding to FAP and its potential to inhibit FAP’s enzymatic activity make it a promising therapeutic agent for cancer. Further research and clinical trials are needed to fully understand its potential and to bring this antibody to the market for the benefit of cancer patients.

Sibrotuzumab, Abbexa, abx831160

Sibrotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FAP, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

Sibrotuzumab ELISA Kit, ProteoGenix, KPTX244

Description of Sibrotuzumab ELISA Kit Sibrotuzumab ELISA Kit: A Powerful Tool for Detecting and Studying the Therapeutic Antibody Introduction Sibrotuzumab is a monoclonal antibody that has been developed as a potential therapeutic agent for cancer treatment. It specifically targets the fibroblast activation protein (FAP), a cell surface protein that is overexpressed in many types of solid tumors. The development of Sibrotuzumab has sparked significant interest in the scientific community due to its potential as a targeted therapy for cancer. In order to facilitate research and development of this promising antibody, a Sibrotuzumab ELISA Kit has been developed, providing a powerful tool for detecting and studying this therapeutic antibody. Structure of Sibrotuzumab Sibrotuzumab is a humanized monoclonal antibody, meaning it is derived from mouse antibodies but has been modified to be more similar to human antibodies. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen binding sites located at the tips of the Y. These binding sites are specific for the FAP protein, allowing Sibrotuzumab to selectively target and bind to FAP-expressing cells. Activity of Sibrotuzumab The primary activity of Sibrotuzumab is its ability to bind to and block the function of FAP. FAP is a cell surface protein that is highly expressed in the tumor microenvironment, making it an attractive target for cancer therapy. FAP has been shown to play a role in tumor growth, invasion, and metastasis, making it a promising therapeutic target. By binding to FAP, Sibrotuzumab can inhibit its function and potentially disrupt the growth and spread of cancer cells. In addition to its direct targeting of FAP, Sibrotuzumab also has immune-mediated effects. It has been shown to activate natural killer (NK) cells, which are a type of immune cell that can destroy cancer cells. This dual mechanism of action makes Sibrotuzumab a potentially powerful therapeutic agent for cancer treatment. Application of Sibrotuzumab ELISA Kit The Sibrotuzumab ELISA Kit is a valuable tool for detecting and studying the therapeutic antibody. ELISA (enzyme-linked immunosorbent assay) is a commonly used laboratory technique that allows for the detection and quantification of specific proteins in a sample. In the case of the Sibrotuzumab ELISA Kit, it is designed to specifically detect and measure the levels of Sibrotuzumab in a sample. The kit includes all the necessary components for performing the ELISA, including pre-coated plates with FAP antigen, Sibrotuzumab standard, and detection antibodies. The procedure involves adding a sample containing Sibrotuzumab to the plate, allowing the antibody to bind to the FAP antigen. The detection antibodies are then added, followed by a colorimetric reaction that can be measured using a spectrophotometer. The intensity of the color is directly proportional to the amount of Sibrotuzumab present in the sample, allowing for accurate quantification. In addition to its use in detecting Sibrotuzumab, the ELISA Kit can also be used to study the pharmacokinetics and pharmacodynamics of the antibody. By measuring the levels of Sibrotuzumab in blood or tissue samples over time, researchers can gain valuable insights into how the antibody is distributed and eliminated from the body. This information can help optimize dosing and treatment regimens for maximum efficacy. Conclusion In summary, the Sibrotuzumab ELISA Kit is a powerful tool for detecting and studying the therapeutic antibody. Its ability to specifically detect and quantify Sibrotuzumab levels in samples makes it an essential tool for research and development of this promising cancer therapy. With its unique structure

Sibrotuzumab ELISA Kit, Abbexa, abx395133

Sibrotuzumab ELISA Kit is a quantitative ELISA kit for detection of Sibrotuzumab.Sibrotuzumab (also known as BIBH 1) is a humanized monoclonal antibody (mAb) which has the high affinity to bind to fibroblast activation protein (FAP), which is highly expressed by stroma cells of tumors. In addition, it was intended and developed by Boehringer Ingelheim Pharma KG for the treatment of cancer. Firstly, this drug was designed to fight against various malignancies, such as colorectal, non-small cell lung, breast, as well as head and neck cancer. However, it is disappointing that in 2003 it failed a phase II clinical trial for metastatic colorectal cancer. At present, there is no relevant clinically approved information disclosure.

Sibrotuzumab Biosimilar - Research Grade, ichor.bio, ICH5860

Research Grade Sibrotuzumab (HC440016), abinScience, HC440016